American Well Corp (AMWL)
0.4878
0.00 (0.00%)
USD |
NYSE |
May 17, 16:00
0.4878
0.00 (0.00%)
After-Hours: 19:10
American Well Research and Development Expense (Quarterly): 26.68M for March 31, 2024
Research and Development Expense (Quarterly) Chart
Historical Research and Development Expense (Quarterly) Data
| Date | Value |
|---|---|
| March 31, 2024 | 26.68M |
| December 31, 2023 | 26.35M |
| September 30, 2023 | 27.72M |
| June 30, 2023 | 25.84M |
| March 31, 2023 | 25.92M |
| December 31, 2022 | 27.68M |
| September 30, 2022 | 36.25M |
| June 30, 2022 | 37.07M |
| March 31, 2022 | 37.48M |
| December 31, 2021 | 33.78M |
| Date | Value |
|---|---|
| September 30, 2021 | 27.40M |
| June 30, 2021 | 22.38M |
| March 31, 2021 | 23.04M |
| December 31, 2020 | 26.56M |
| September 30, 2020 | 25.28M |
| June 30, 2020 | 17.64M |
| March 31, 2020 | 14.94M |
| December 31, 2019 | 14.77M |
| September 30, 2019 | 13.60M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
13.60M
Minimum
Sep 2019
37.48M
Maximum
Mar 2022
25.81M
Average
26.35M
Median
Dec 2023
Research and Development Expense (Quarterly) Benchmarks
| Ontrak Inc | 1.893M |
| GoodRx Holdings Inc | 31.02M |
| Privia Health Group Inc | -- |
| Doximity Inc | 19.95M |
| GeneDx Holdings Corp | 11.57M |